Ämnen: Farmaci

AstraZeneca PLC: Delårsrapport för första kvartalet 2015 - sammanfattning. Bifogat finns den fullständiga rapporten

24 April 2015 08:06

Det finansiella resultatet för kvartal 1 2015 ger stöd åt upprepad helårsprognos för 2015.
oTotala intäkter (definierat som produktförsäljning och intäkter från externa samarbeten1) ökade med 1% i fasta valutakurser 2 (CER) till 6 057 MUSD (Q1 2014: 6 460 MUSD)
oVinst per aktie för kärnverksamheten (Core EPS) minskade med 3% till1,08 USD i takt med att vi fortsätter att investera i att uppn

AstraZeneca enters strategic immuno-oncology collaboration with Celgene Corporation to develop PD-L1 inhibitor programme for patients with serious blood cancers

24 April 2015 07:05

AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into an exclusive collaboration agreement with Celgene Corporation, a global leader in haematological cancers, for the development and commercialisation of MEDI4736

AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology

24 April 2015 07:00

AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into a collaboration to accelerate and broaden the development of Innate Pharma SA’s proprietary anti-NKG2A antibody

Insatser för svensk kardiolgi uppmärksammas: Berglind Libungans får 2015 års stipendium inom akuta koronara syndrom utlyst av Svenska Kardiologföreningen och AstraZeneca

23 April 2015 13:30

Idag tilldelas Berglind Libungans, verksam vid enheten för kardiologi, Sahlgrenska Universitetssjukhuset i Göteborg ett forskningsstipendium på 120 000 kr.

AstraZeneca and Bina collaborate to deploy genomic management solution in R&D

21 April 2015 13:08

AstraZeneca and Bina Technologies, Inc., a member of the Roche Group, today announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Programme

AstraZeneca tillkännager uppdaterade data om progressionsfri överlevnad för forskningssubstansen AZD9291 mot icke småcellig lungcancer

17 April 2015 09:03

Uppdaterade data som presenterades vid European Lung Cancer Conference 2015 visar en fördröjning av tumörprogression på över ett år

Selumetinib granted Orphan Drug Designation by US FDA for treatment of uveal melanoma

17 April 2015 08:01

AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma.

Medimmune and Immunocore announce new collaboration to conduct immuno-oncology combination trials in melanoma

16 April 2015 08:02

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a collaboration to conduct clinical trials in immuno-oncology with Immunocore Limited, a privately-held UK-based biotechnology company.

Tremelimumab har beviljats särläkemedelsstatus av FDA för behandling av malignt mesoteliom

15 April 2015 08:04

​AstraZeneca meddelar i dag att den amerikanska läkemedelsmyndigheten (Food and Drug Administration, FDA) har beviljat särläkemedelsstatus åt den monoklonala anti-CTLA-4-antikroppen tremelimumab för behandling av malignt mesoteliom.

FDA Advisory Committee reviews SAVOR outcomes study results for ONGLYZA® and KOMBIGLYZE® XR

15 April 2015 08:03

AstraZeneca today announced that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 13to 1(1 abstained; 15 total votes) that the results of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with

AstraZeneca to showcase strong oncology science at American Association for Cancer Research annual meeting 2015

13 April 2015 08:03

•More than 60 scientific abstracts to be featured at the meeting, highlighting the breadth and depth of AstraZeneca’s oncology pipeline and ability to test a range of small molecule and biologic combinations.

NYTT BEHANDLINGSALTERNATIV FÖR FÖRSTOPPNING ORSAKAD AV OPIOIDER

1 April 2015 09:42

Nu finns AstraZenecas läkemedel Moventig® (naloxegol) tillgängligt i Sverige, som första land i Europa. Läkemedlet är avsett för att behandla förstoppning orsakad av smärtlindrande läkemedel innehållande opioider hos vuxna patienter som upplevt otillräcklig effekt av laxermedel

AstraZeneca to collaborate with the Harvard Stem Cell institute in diabetes

25 Mars 2015 08:04

AstraZeneca today announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.

AstraZeneca och Daiichi Sankyo kommer att marknadsföra MOVANTIK gemensamt i USA

19 Mars 2015 08:03

AstraZeneca meddelar idag att man ingått ett samarbetsavtal med Daiichi Sankyo Inc. avseende marknadsföring av MOVANTIK™ (naloxegol) i USA.

AstraZeneca announces positive phase III top-line results for PT003 from the PINNACLE 1 and PINNACLE 2 studies in COPD

18 Mars 2015 08:06

AstraZeneca today announced positive top-line results from the Phase III PINNACLE programme, which included two pivotal 24-week studies (PINNACLE 1 and PINNACLE 2) to investigate the potential of PT003 to improve lung function in patients with Chronic Obstructive Pulmonary Disease (COPD).

PEGASUS-TIMI 54 studien visar att långtidsbehandling med BRILINTA/BRILIQUE minskade aterotrombotiska händelser hos patienter med tidigare hjärtinfarkt

14 Mars 2015 16:07

Data från en studie med 21 000 patienter presenterades på den 64:e årliga vetenskapliga kongressen som hålls av American College of Cardiology och publicerades parallellt i New England Journal of Medicine

AstraZeneca refines its financial reporting in line with evolving business model

5 Mars 2015 19:28

AstraZeneca today announces an update to the presentation of its Statement of Comprehensive Income, which will see revenue from externalisation becoming more visible to enhance transparency for investors. The change is effective from 1 January 2015 and will be reported as part of the Company’s first quarter financial results on 24 April 2015.

AstraZeneca to participate in US FDA Endocrinologic and Metabolic Drugs Advisory Committee

4 Mars 2015 13:02

AstraZeneca today announced it will participate in the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on 14 April 2015 to discuss the results of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial for ONGLYZA® (saxagliptin) and Kombiglyze® XR (saxagliptin and metformin HCI extended-release).

AstraZeneca completes acquisition of rights to Actavis’ branded respiratory portfolio in the US and Canada

3 Mars 2015 08:22

Acquisition strengthens AstraZeneca’s aclidinium respiratory franchise and adds immediate revenues with long-term growth potential

AstraZeneca announces Non-Executive Board changes

17 Februari 2015 08:03

AstraZeneca today announced that Dr Cornelia (Cori) Bargmann will be proposed to shareholders for election as a Non-Executive Director at the Company’s Annual General Meeting (AGM) on 24 April 2015.On election, the Board also proposes appointing Dr Bargmann to AstraZeneca’s Science Committee.
Cori is the Torsten N. Wiesel Professor and head of the Lulu and Anthony Wang Laboratory of Neural Circ